

Gene Therapy in Subjects With Biallelic RPE65 Mutation-associated Retinal Dystrophy

NCT05858983

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	Frontera Therapeutics
Enrollment	9 participants

Key Eligibility Criteria

Inclusion (3)

- Subjects who are able to understand and sign the ICF
- Female or male aged 8-45 years old when signing the ICF
- Clinically diagnosed with biallelic RPE65 mutation-associated retinal dystrophy

Exclusion (7)

- Other interfering eye diseases
- Presence of any systemic or ocular disease that can cause or likely to cause vision loss
- There is evidence of obviously uncontrolled concomitant diseases
- Known to have active or suspected autoimmune diseases
- With active systemic infection under treatment
- ... and 2 more (see full listing online)

Locations (1 total)

Peking Union Medical College Hospital, Beijing, Beijing Municipality, China